Recent clinical studies have shown that SGLT-2 inhibitors significantly reduce the hospitalization rates for heart failure and the risk of cardiovascular death in CKD patients, while effectively managing metabolic diseases like obesity and hyperuricemia (136). This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.